Особливості відновлення овуляторної функції у жінок

O.V. Bulavenko; O.V. Furman; O.L. Ocheretna; V.V. Kelman

doi:10.18370/2309-4117.2021.60.96-100

Authors

O.V. Bulavenko Vinnytsya National Pirogov Memorial Medical University; Reproductive Medicine Сlinic “Remedyvin”, Vinnytsia , Ukraine https://orcid.org/0000-0003-1207-9046
O.V. Furman Vinnytsia National Pirogov Memorial Medical University, Vinnytsia , Ukraine https://orcid.org/0000-0001-6874-3271
O.L. Ocheretna Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine https://orcid.org/0000-0001-7895-2931
V.V. Kelman Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine https://orcid.org/0000-0003-0927-0851

DOI:

https://doi.org/10.18370/2309-4117.2021.60.96-100

Keywords:

ovulatory dysfunction, insulin resistance, polycystic ovary syndrome, glucose tolerance test, free testosterone index, myo-inositol

Abstract

Myo-inositol is considered an additional insulin-sensitive supplement that may benefit women with polycystic ovary syndrome (PCOS). Correcting insulin resistance and lowering circulating insulin levels are key therapeutic options in the PCOS treatment, which in turn increase fertility and reduce the risk of type 2 diabetes and early cardiovascular diseases.
Research objective: to determine the effectiveness of the Miofolic drug (contains myo-inositol 2000 mg, 5-methyltetrahydrofolate 200 μg, vitamin B12 2,5 μg) for the restoration of ovulatory dysfunction in women with PCOS phenotype A (ovulatory dysfunction + hyperandrogenism + polycystic ovarian structure).
Materials and methods. The study included 60 women of reproductive age with PCOS phenotype A. 31 patients (group І) had normal weight, 29 patients (group ІІ) were overweight. Patients of both clinical groups received therapy with Miofolic 2 sachets for 6 months. Also, women in both groups were given recommendations for lifestyle modifications and a diet with limited carbohydrate content.
Treatment efficacy was monitored after 3 and 6 months by determining body mass index, free testosterone index, 75 g glucose tolerance test, progesterone levels in the second phase of the menstrual cycle and ultrasound folliculometry.
Results. In the first group, ovulatory cycles resumed after 3 months in 38.7% of patients (p < 0.05), and after 6 months in 58.06% (p < 0.01). In the second group, ovulatory cycles resumed after 3 months in 34.4% of women (p < 0.05), and after 6 months in 41.3% (p < 0.05).
Conclusions. The results of this study allow us to recommend the Miofolic drug as the main method of inducing ovulation in women with PCOS with and without overweight, the period of the drug use is from 3 to 6 months. A more stable restoration of ovulatory function occurs after 6 months of therapy.

Author Biographies

O.V. Bulavenko, Vinnytsya National Pirogov Memorial Medical University; Reproductive Medicine Сlinic “Remedyvin”, Vinnytsia

MD, professor, head of Obstetrics and Gynecology Department No. 2;
Head of the Reproductive Medicine Сlinic

O.V. Furman, Vinnytsia National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor at the Obstetrics and Gynecology Department No. 2

O.L. Ocheretna, Vinnytsia National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor, Department of Normal Physiology

V.V. Kelman, Vinnytsia National Pirogov Memorial Medical University, Vinnytsia

Postgraduate student, Obstetrics and Gynecology Department No. 2

References

Islamova, H.О. “Pregravid preparation of women with polycystic ovary syndrome.” Reproductive Endocrinology 53 (2020): 30–4. DOI: 10.18370/2309-4117.2020.53.30-34
Kalugina, L.V., Yusko, T.I. “Myo-inositol therapeutic possibilities and pregnancy preparation for polycystic ovary syndrome (literature review).” Reproductive endocrinology 4.42 (2018): 40–5. DOI: 10.18370/2309-4117.2018.42.40-45
Kapshuk, I.M., Islamova, H.О. “Features of treatment of polycystic ovary syndrome in women with metabolic syndrome.” A word about health 13.1 (2018): 32–6.
Kaminsky, V.V., Tatarchuk, T.F., Dubossarska, Y.O. “National consensus on the management of patients with hyper -androgenism.” Reproductive endocrinology 4.30 (2016): 19–31.
Nosenko, O.M., Novikova, O.V. “Inositols in reproductive medicine.” Reproductive Endocrinology 6.56 (2020): 23–34. DOI: 10.18370/2309-4117.2020.56.23-34
Brown, J. B. “Types of ovarian activity in women and their significance: the continuum (a reinterpretation of early findings).“ Human Reproduction Update 17.2 (2011): 141-158. DOI: 10.1093/humupd/dmq040
Contreras, P. H., Vigil, P. “Letter to the Editor:“Long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels”.“ The Journal of Clinical Endocrinology & Metabolism 104.3 (2019): 678–679. DOI: 10.1210/jc.2018-01598
Contreras, P.H., Salgado, A.M., Bernal, Y.A., Vigil, P.H. “A simple and improved predictor of insulin resistance extracted from the oral glucose tolerance test: the I0* G60.“ Journal of the Endocrine Society 3.6 (2019): 1154–1166. DOI: 10.1210/js.2018-00342
Contreras, P.H., Serrano, F.G., Salgado, A.M., Vigil, P. “Insulin sensitivity and testicular function in a cohort of adult males suspected of being insulin-resistant.” Frontiers in medicine 5 (2018): 190. DOI: 10.3389/fmed.2018.00190
Lunenfeld, B., Insler, V. “Follicular development and its control.” Gynecology and Endocrinology 7 (1993): 285–291. DOI: 10.3109/09513599309152514
Malcolm, C.E., Cumming, D.C. “Does anovulation exist in eumenorrheic women?” Obstetrics & Gynecology 102.2 (2003): 317–318. DOI: 10.1016/S0029-7844(03)00527-1
Motta, P.M., Sayoko, M., Notttola, S.A. “The ultrastructure of human reproduction. The natural history of the female germ cell: origin, migration and differentiation inside the developing ovary.” Human reproduction update 3.3 (1997): 281–297. DOI: 10.1093/humupd/3.3.281
Ozay, A.C., Emekci Ozay, O., Okyay, R.E., et al. “Different effects of myoinositol plus folic acid versus combined oral treatment on androgen levels in PCOS women.” International Journal of Endocrinology (2016): 1–8. DOI: 10.1155/2016/3206872
Pollak, F., Araya, V., Lanas, A., Sapunar, J. “II Consenso de la Sociedad Chilena de Endocrinología y Diabetes sobre resistencia a la insulina.” Rev Med Chile 143 (2015): 637–650.
Prague, J.K., Dhillo, W.S. “Treating hot flushes with a neurokinin 3 receptor antagonist.” Oncotarget 2017; 8: 106153–106154. DOI: 10.18632/oncotarget.22383
Priyanka, B., Kumari, G.A., Raju, J., Shankaraiah, P. “Role of kisspeptin in livestock reproduction.” Pharm Innov J 7 (2018): 728–731.
Rance, N.E., Dacks, P.A., Mittelman-Smith, M.A., et al. “Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes.” Frontiers in neuroendocrinology 34.3 (2013): 211–227. DOI: 10.1016/j.yfrne.2013.07.003
Uenoyama, Y., Inoue, N., Nakamura, S., Tsukamura, H. “Central mechanism controlling pubertal onset in mammals: A triggering role of kisspeptin.” Frontiers in endocrinology 10 (2019): 312. DOI: 10.3389/fendo.2019.00312
Vigil, P., del Río, J.P., Carrera, B., et al. “Influence of sex steroid hormones on the adolescent brain and behavior: an update.” Linacre Q 83 (2016): 308–329. DOI: 10.1080/00243639.2016.1211863
Vigil, P., Lyon, C., Flores, B., et al. “Ovulation, a sign of health.” Linacre Q 84 (2017): 343–355. DOI: 10.1080/00243639.2017.1394053
Vitagliano, A., Saccone, G., Cosmi, E., et al. “Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials.” Archives of gynecology and obstetrics 299.1 (2019): 55–68.
Vucenik, I. “Anticancer properties of inositol hexaphosphate and inositol: An overview.” Journal of nutritional science and vitaminology 65 (2019): 18–22. DOI: 10.3177/jnsv.65.S18
Wojciechowska, A., Osowski, A., Jóźwik, M., et al. “Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.” International journal of molecular sciences 20.22 (2019): 5787. DOI: 10.3390/ijms20225787